Advertisement

Search Results

Advertisement



Your search for Caroline Helwick matches 1983 pages

Showing 1 - 50


colorectal cancer
immunotherapy

Chiara Cremolini, MD, PhD, Comments on Findings From the PARADIGM Trial

The invited discussant of PARADIGM, Chiara Cremolini, MD, PhD, Professor of Medical Oncology at the University of Pisa, Italy, said the findings prospectively confirm the superior benefit of FOLFOX (fluorouracil, leucovorin, oxaliplatin) paired with panitumumab rather than bevacizumab in RAS...

colorectal cancer
immunotherapy

In Metastatic RAS Wild-Type Left-Sided Colorectal Cancer, Panitumumab Proves Superior to Bevacizumab

The preferred targeted therapy for left-sided RAS wild-type metastatic colorectal cancer, in combination with standard chemotherapy, is panitumumab, not bevacizumab, based on a head-to-head comparison in the phase III PARADIGM trial. Panitumumab plus chemotherapy yielded the longest overall...

Expert Point of View: Joseph Mikhael, MD, MEd

Invited discussant of the ­DETERMINATION trial, Joseph Mikhael, MD, MEd, Professor of Applied Cancer Research and Drug Discovery at the Translational Genomics Research Institute, City of Hope Cancer Center, described the many implications of the important findings for DETERMINATION and offered some ...

hematologic malignancies

Early Transplant With Triplet Therapy May Delay Progression of Myeloma, but Individualized Approach Recommended

In the phase III DETERMINATION trial, progression-free survival was significantly improved with triplet induction therapy and early transplantation in newly diagnosed patients with multiple myeloma, but overall survival at 5 years was similar to the nontransplant approach.1 The findings were...

pancreatic cancer
immunotherapy

Expert Point of View: Thomas Seufferlein, MD

Thomas Seufferlein, MD, Professor of Medicine at Ulm University Hospital in Germany, found the data from the NOTABLE trial1 encouraging and “clinically interesting.” However, he suggested the study’s design did not allow the EGFR inhibitor to be optimally tested. The NOTABLE trial is based on a...

pancreatic cancer
genomics/genetics
immunotherapy

NOTABLE Trial: Survival in Pancreatic KRAS Wild-Type Cancer Improved With Addition of Nimotuzumab to Gemcitabine

In patients with locally advanced or metastatic pancreatic cancer and KRAS wild-type tumors, novel treatment with the monoclonal antibody nimotuzumab, which targets the epidermal growth factor receptor (EGFR),  plus gemcitabine significantly improved overall survival and other outcomes over...

breast cancer
immunotherapy

Expert Point of View: Debu Tripathy, MD

Debu Tripathy, MD, Professor and Chair of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, shared his thoughts on TROPiCS-02 with The ASCO Post. He said the study is important because it addresses the needs of “a population with limited options, whose...

breast cancer
immunotherapy

TROPiCS-02 Sacituzumab Govitecan Effective in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

For advanced breast cancer that is hormone receptor–positive and HER2-negative, sacituzumab govitecan-hziy significantly reduced the risk of disease progression by 34% over physician’s choice of treatment, based on the results of the phase III TROPiCS-02 trial.1 The heavily pretreated patients in...

colorectal cancer
immunotherapy

Expert Point of View: Kimmie Ng, MD, MPH

The study’s invited discussant was Kimmie Ng, MD, MPH, Associate Professor of Medicine at Harvard Medical School and Co-Director of the Colon and Rectal Cancer Center at Dana-Farber Cancer Institute, Boston. “Neoadjuvant dostarlimab-gxly for 6 months represents a promising new treatment for...

colorectal cancer
immunotherapy

100% Complete Response Rate in 14 Patients With Rectal Cancer Treated With Neoadjuvant Dostarlimab-gxly

In a study of 18 patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of neoadjuvant treatment with the anti–PD-1 agent dostarlimab-gxly alone led to clinical complete responses in 100% of the study’s first 14 patients.1 These results were presented at the 2022...

Expert Point of View: Mafalda Oliveira, MD, PhD

The invited discussant of the TUXEDO-1 trial1 was Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona. Dr. Oliveira noted that 40% of the 15 patients in TUXEDO-1 had symptomatic disease, and 60% had central nervous system metastases...

breast cancer
immunotherapy

T-DXd Shows Efficacy Against Active Brain Metastases in HER2-Positive Breast Cancer

In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...

Expert Point of View: Mafalda Oliveira, MD, PhD

The invited discussant of the BEGONIA trial,1 Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, called the activity of the combination of durvalumab and datopotamab deruxtecan (Dato-DXd) “notable,” with a 74% response rate overall,...

breast cancer
immunotherapy

BEGONIA Trial Reports Activity With Datopotamab Deruxtecan Plus Durvalumab in Triple-Negative Breast Cancer

Preliminary results of the basket BEGONIA trial showed that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), paired with the immune checkpoint inhibitor durvalumab, has strong activity in advanced or metastatic triple-negative breast cancer among patients not biomarker-selected for...

Expert Point of View: Mafalda Oliveira, MD, PhD

Invited discussant of the MONALEESA-3 trial, Mafalda Oliveira, MD, PhD, of Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, commented: “I totally agree with the authors when they say these results are ‘impressive.’” Among all the phase III trials evaluating...

breast cancer

MONALEESA-3: Ribociblib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting

In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, first-line treatment with ribociclib plus fulvestrant added nearly 16 months of overall survival time vs fulvestrant...

colorectal cancer
immunotherapy

'Unprecedented' 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly

Rarely, if ever, has one abstract presented at the ASCO Annual Meeting warranted its own session—but that happened with a small but mighty study from Memorial Sloan Kettering. In a study of patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of treatment with the ...

multiple myeloma

Multiple Myeloma: Treatment Conundrums

The availability of numerous new agents for treating multiple myeloma has created some “conundrums” for clinicians, said Sergio Giralt, MD, Deputy Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center and the Melvin Berlin Family Chair in Myeloma Research and...

issues in oncology

Drug Developers Share Thoughts on the Oncology Pipeline and the Changes in Clinical Trials

Two oncologists who are now heads of oncology development for pharmaceutical companies discussed the future of cancer drugs at the Community Oncology Alliance’s 2022 Community Oncology Conference. They were ­Johanna Bendell, MD, Global Head of Oncology, Pharma Research, and Early Development at...

gastrointestinal cancer
breast cancer
survivorship
multiple myeloma
lymphoma

NCCN Clinical Practice Guidelines in Oncology: 2022 Updates

In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology® covering eight tumor types. Guidelines are now published for more than 60 tumor types, subtypes, and topics. During the NCCN’s 27th Annual Conference, which was again...

breast cancer

Sentinel Node May Not Be Informative in Making Treatment Decisions for Some Breast Cancer Subsets

In women aged 70 and older with hormone receptor–positive, HER2-negative, low-risk breast cancers, sentinel lymph node biopsy may not be a reliable indicator of the need for adjuvant chemotherapy, researchers reported at the 2022 American Society of Breast Surgeons Annual Meeting.1 “We found that...

breast cancer

Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer

In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with advanced/metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, first-line treatment with ribociclib plus fulvestrant lengthened overall survival by approximately 16 months vs...

breast cancer
immunotherapy

TUXEDO-1: Efficacy of T-DXd for Patients With HER2-Positive Breast Cancer and Active Brain Metastases

In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yielding intracranial responses in 73.3% of the population and a median progression-free survival of...

multiple myeloma
immunotherapy

Bispecific Antibodies With Multiple Targets Moving Forward in Multiple Myeloma

Poor outcomes are observed in patients with myeloma who are refractory to multiple classes of therapies, with the average patient experiencing disease progression in up to 6 months and living no longer than 6 to 15 months. Patients often rapidly cycle through regimens that use less effective or...

Expert Point of View: Joseph Mikhael, MD

The ASCO Post asked Joseph Mikhael, MD, Chief Medical Officer of the International Myeloma Foundation and Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (an affiliate of City of Hope Cancer Center), to comment on the GMMG-HD7...

multiple myeloma

Isatuximab-Containing Induction Therapy for Multiple Myeloma Increases Measurable Residual Disease Negativity

For the first-line treatment of newly diagnosed multiple myeloma, the percentage of patients achieving measurable residual disease (MRD, previously called minimal residual disease) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to a standard...

Expert Point of View: Jane N. Winter, MD and Christopher R. Flowers, MD, MS

Jane N. Winter, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and the 2022 President of the American Society of Hematology (ASH), and Christopher R. Flowers, MD, MS, Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer...

lymphoma

POLARIX: Addition of Polatuzumab Vedotin-piiq to Standard of Care Significantly Reduces Progression of Diffuse Large B-Cell Lymphoma

As a first-line treatment of inter-mediate- or high-risk diffuse large B-cell lymphoma, the addition of the antibody-drug conjugate polatuzumab vedotin-piiq to standard-of-care therapy resulted in a 27% reduction in the relative risk of disease progression, relapse, or death, with a similar safety...

Expert Point of View: Laurie H. Sehn, MD, MPH and Alex Herrera, MD

Laurie H. Sehn, MD, MPH, Clinical Professor with the BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada, and Alex Herrera, MD, Associate Professor in Hematology and Hematopoietic Cell Transplantation at the Beckman Research Institute of City of Hope,...

lymphoma

ZUMA-7: Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma

In the primary analysis of the phase III ZUMA-7 trial, examining second-line therapy for relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard of care. These findings were presented at the...

lymphoma
leukemia

Zanubrutinib Superior to Ibrutinib for CLL/SLL in Phase III ALPINE Trial

Zanubrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, significantly improved response rates and delayed disease progression as compared with the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...

breast cancer
immunotherapy

Demystifying Immunotherapy for Early-Stage Triple-Negative Breast Cancer

Immunotherapy has become a potential strategy in treating triple-negative breast cancer, though many questions remain to be answered before long-term survival is achieved by all patients. This exciting field of breast cancer research was explored at the 2022 Miami Breast Cancer Conference by...

Expert Point of View: Mikkael Sekeres, MD

Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System and a hematologist at Sylvester Comprehensive Cancer Center, applauded the IDIOME1 and IDEAL2 investigators for conducting studies. These studies, he noted, were “very difficult because of the rarity...

hematologic malignancies

IDH1/2 Inhibitors Show Activity in Patients With Myelodysplastic Syndrome

The oral targeted small-molecule inhibitors of mutant IDH1 and IDH2 appear to be active in patients with myelodysplastic syndrome (MDS) harboring these mutations, according to two phase II trials by the Groupe Francophone des Myélodysplasies (GFM) and its German colleagues in the European MDS...

Expert Point of View: Amit M. Oza, MD, MBBS

The invited discussant of the phase III ­ENGOT-EN5/GOG-3055/SIENDO trial was Amit M. Oza, MD, MBBS, Head of the Division of Medical Oncology & Hematology at University Health Network/Mount Sinai, Director of Clinical Research and Clinical Cancer Research Unit at Princess Margaret Hospital, and ...

gynecologic cancers

Selinexor Improves Progression-Free Survival in Endometrial Cancer

In the treatment of advanced endometrial cancer, maintenance therapy with oral selinexor after response to first-line chemotherapy may result in a significantly reduced risk of disease progression, according to the results of the global phase III ENGOT-EN5/GOG-3055/SIENDO trial, presented at the...

Expert Point of View: Adil Daud, MBBS, and Georgina V. Long, MBBS, PhD

The invited discussant of the RELATIVITY-047 trial, Adil Daud, MBBS, said the findings1 “mark a major advance for immunotherapy beyond CTLA-4 and PD-1” as upfront treatment for advanced melanoma. However, the findings trigger a host of questions for clinicians. Dr. Daud is Co-Director of the...

skin cancer

RELATIVITY-047 Update: Novel Immunotherapy Duo Delays Disease Progression in Advanced Melanoma

A novel immunotherapeutic combination that targets PD-1 and the LAG-3 pathway significantly delayed disease progression as a first-line treatment of advanced or unresectable melanoma. Updated results of the global phase III RELATIVITY-047 trial validated the study’s initial findings and were...

hematologic malignancies
genomics/genetics

John Mascarenhas, MD, on the Implications of the FIGHT-203 Trial

John Mascarenhas, MD, Director of the Adult Leukemia Program at The Tisch Cancer Institute at Mount Sinai, New York, commented on the implications of the FIGHT-203 trial, which evaluated pemigatinib in myeloid or lymphoid neoplasms. Pemigatinib is an oral small-molecule receptor tyrosine kinase...

hematologic malignancies
genomics/genetics

Study Shows Pemigatinib Activity in Treatment of Myeloid or Lymphoid Neoplasms With FGFR1 Rearrangement

In patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements, pemigatinib produced high and durable response rates, despite patients’ extensive use of prior treatments or hematopoietic stem cell transplantation (HSCT), according to the early results of the multicenter phase II FIGHT-203 ...

head and neck cancer
immunotherapy

Tislelizumab Plus Chemotherapy Improves Progression-Free Survival in Nasopharyngeal Cancer

The addition of the checkpoint inhibitor tislelizumab to first-line chemotherapy significantly reduced the risk of disease progression or death by 50% and, despite a 49% crossover rate, numerically boosted overall survival in patients with recurrent or metastatic nasopharyngeal cancer, Zhang et al...

lymphoma

Mantle Cell Lymphoma Previously Treated With BTK Inhibitor May Respond to a Newer BTK Inhibitor

The next-generation inhibitor of Bruton’s tyrosine kinase (BTK) may be effective in mantle cell lymphoma for patients previously treated with an older BTK inhibitor, according to results from the phase I/II BRUIN trial. These findings were reported at the 2021 American Society of Hematology (ASH)...

colorectal cancer

Changes in the NCCN Guidelines on Colorectal Cancer Screening

The National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening have recently incorporated significant changes, reflecting recommendations that will spare some patients unnecessary interventions and, in other cases, detect cancer earlier. The ...

breast cancer
genomics/genetics

Expert Point of View: Mark E. Robson, MD

“OlympiA is clearly a practice-changing trial, and olaparib should be offered to patients meeting the entry criteria for the study,” said Mark E. Robson, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Dr. Robson was invited to discuss the findings of...

breast cancer
genomics/genetics

OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer

The OlympiA trial of adjuvant olaparib in patients with HER2-negative, high-risk ­early-stage breast cancer and BRCA1 and BRCA2 mutations has now demonstrated a significant overall survival benefit, reducing the risk of death over placebo by 32% and yielding an absolute improvement of 3.8% at 3...

breast cancer
supportive care

Advances in Managing Cardiac Side Effects Associated With Breast Cancer Treatment

Guideline-directed medical therapy for the prevention and treatment of cardiotoxicity is improving quality of life and oncologic outcomes associated with breast cancer treatment, according to Jean-Bernard Durand, MD, FACP, FCCP, FACC, FHFSA, Professor of Medicine at The University of Texas MD...

breast cancer

Emerging Endocrine Therapies for the Management of Breast Cancer

Novel hormonal therapies for breast cancer could provide additional therapeutic options for patients with hormone receptor–positive breast cancer. The emerging landscape for these new agents was described at the 2022 Miami Breast Cancer Conference, sponsored by PER, by Aditya Bardia, MD, MPH,...

Expert Point of View: E. Gabriela Chiorean, MD

The invited discussant of the CodeBreaK 100 data, E. Gabriela Chiorean, MD, Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center, and Clinical Director of the Gastrointestinal Medical Oncology program at Seattle Cancer Care Alliance, found the efficacy...

pancreatic cancer

CodeBreaK 100: Sotorasib Shows Activity in KRAS G12C–Mutated Pancreatic Cancer

Promising activity in metastatic pancreatic cancer was shown by sotorasib, an inhibitor of the KRAS G12C mutation, in the phase I/II CodeBreaK 100 study presented by John H. Strickler, MD, Associate Professor of Medicine at Duke University Medical Center in Durham, North Carolina, during the...

breast cancer

PARP Inhibitors in the Treatment of Breast Cancer: What’s Next?

In patients with breast cancer tumors harboring BRCA1 and BRCA2 mutations, inhibitors of poly (ADP-ribose) polymerase (PARP) have emerged as essential therapeutic agents. What more needs to be done to obtain even more benefit from these targeted agents? This question was tackled at the 2022 Miami...

Advertisement

Advertisement



Advertisement